Rockefeller Capital Management
ORMP icon

Rockefeller Capital Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Rockefeller Capital Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,000
Closed -$48K – 3299
2022
Q4 		$48K Hold
4,000
– – ﹤0.01% 2409
2022
Q3 		$25K Hold
4,000
– – ﹤0.01% 2675
2022
Q2 		$18K Hold
4,000
– – ﹤0.01% 2809
2022
Q1 		$34K Hold
4,000
– – ﹤0.01% 2486
2021
Q4 		$57K Buy
+4,000
New +$83.6K ﹤0.01% 2160

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SIGI
Susquehanna International Group (Ireland) Dublin, Ireland $472M AUM 25.62% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Rockefeller Capital Management's ORMP Position: Q1 2023 in Review

Rockefeller Capital Management sold out of Oramed Pharmaceuticals (ORMP) in Q1 2023, closing a stake of 4,000 shares — an estimated $48K sold.

Rockefeller Capital Management first reported a position in ORMP in Q4 2021 and held it in 5 quarters. The position peaked at $57K in Q4 2021. 61 funds tracked by Wall St. Rank hold ORMP as of Q1 2023.

  • Rockefeller Capital Management reported no remaining Oramed Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 4,000 Oramed Pharmaceuticals shares in Q1 2023, an estimated $48K.
  • Rockefeller Capital Management first reported a position in Oramed Pharmaceuticals in Q4 2021 and held it in 5 quarters.
  • Rockefeller Capital Management's Oramed Pharmaceuticals position peaked at $57K in Q4 2021.
  • 61 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.